Aristides Capital’s Lipocine LPCN Stock Holding History

Aristides Capital’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-8,626	Closed	-$199K	–	147
2020 Q4	$199K	Buy	+8,626	New	+$208K	0.07%	115

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Aristides Capital's LPCN Position: Q1 2021 in Review

Aristides Capital sold out of Lipocine (LPCN) in Q1 2021, closing a stake of 8,626 shares — an estimated $199K sold.

Aristides Capital first reported a position in LPCN in Q4 2020 and held it in 1 quarter. The position peaked at $199K in Q4 2020. 42 funds tracked by Wall St. Rank hold LPCN as of Q1 2021.

Aristides Capital reported no remaining Lipocine position as of Q1 2021 after selling out during the quarter.
Aristides Capital sold 8,626 Lipocine shares in Q1 2021, an estimated $199K.
Aristides Capital first reported a position in Lipocine in Q4 2020 and held it in 1 quarter.
Aristides Capital's Lipocine position peaked at $199K in Q4 2020.
42 funds tracked by Wall St. Rank held Lipocine as of Q1 2021.

Based on Aristides Capital's 13F filing for Q1 2021, filed 17 May 2021.